TARCEVA Side Effects

6786187-4 | Bronchopneumonia, Febrile Neutropenia
on Jun 22, 2010 Female patient from UNITED STATES , weighting 145.9 lb, was treated with Tarceva (View Usage). Patient experienced the following unwanted or unexpected effects: bronchopneumonia, febrile neutropenia. Tarceva dosage: . During the same period patient was treated with VIDAZA (View Vidaza Review and Vidaza Label ). Patient was hospitalized.

6785130-1 | Disease Complication, Haematuria, International Normalised Ratio Increased, Rash, Superinfection, Ulcer
Patient was taking Tarceva (View Usage). Patient had the following side effects: disease complication, haematuria, international normalised ratio increased, rash (What is rash?), superinfection, ulcer (What is ulcer?) on Jun 03, 2010 from FRANCE Additional patient health information: Male patient , 87 years of age, was diagnosed with lung neoplasm malignant and. Tarceva dosage: 150 Mg, Qd, Oral. During the same period patient was treated with PREVISCAN (FLUINDIONE) (View Previscan (fluindione) Review and Previscan (fluindione) Label ). Patient was hospitalized.

6784200-1 |
Adverse event was reported on Jun 02, 2010 by a Male patient taking Tarceva (View Usage) (Dosage: Oral) . Location: UNITED STATES , 63 years of age, .

6783524-1 | Deafness, Diarrhoea
on Jun 03, 2010 Female patient from UNITED STATES , 50 years of age, was diagnosed with lung neoplasm malignant and was treated with Tarceva (View Usage). Patient experienced the following unwanted or unexpected effects: deafness, diarrhoea. Tarceva dosage: 100 Mg, Qd, Oral.


6783059-6 | Dysphagia, Pyrexia, Rash, Stomatitis
on Jun 02, 2010 Male patient from INDIA , 58 years of age, was diagnosed with non-small cell lung cancer and was treated with Tarceva (View Usage). Patient had the following side effects: dysphagia, pyrexia, rash (What is rash?), stomatitis. Tarceva dosage: 150 Mg, Qd, Oral. During the same period patient was treated with TELMISARTAN (View Telmisartan Review and Telmisartan Label ), LEVOTHYROXINE SODIUM (View Levothyroxine Sodium Review and Levothyroxine Sodium Label ), HYPOGLYCEMIC NOS (View Hypoglycemic Nos Review and Hypoglycemic Nos Label ), ATIVAN (View Ativan Review and Ativan Label ), GABAPENTIN (View Gabapentin Review and Gabapentin Label ), PHENYTOIN (View Phenytoin Review and Phenytoin Label ). Patient was hospitalized.

6782987-5 | Decubitus Ulcer, Pleural Effusion
Patient was taking Tarceva (View Usage). After Tarceva was administered, patient had the following side effects: decubitus ulcer, pleural effusion on Jun 01, 2010 from JAPAN Additional patient health information: Female patient , 49 years of age, was diagnosed with lung adenocarcinoma and. Tarceva dosage: Oral.

6782837-7 | Haemoptysis
Adverse event was reported on Jun 01, 2010 by a Male patient taking Tarceva (View Usage) (Dosage: (150 Mg, Qd), Oral) was diagnosed with lung neoplasm malignant and. Location: UNITED STATES , 64 years of age, Patient experienced the following unwanted or unexpected effects: haemoptysis.

6782835-3 | Blood Calcium Increased
on Jun 01, 2010 Female patient from UNITED STATES , 58 years of age, was diagnosed with non-small cell lung cancer and was treated with Tarceva (View Usage). Patient had the following side effects: blood calcium increased. Tarceva dosage: (150 Mg, Qd), Oral. Patient was hospitalized.

6780890-8 | Dialysis, Pleural Effusion, Renal Failure Acute, Urinary Retention
on May 31, 2010 Male patient from JAPAN , 77 years of age, was diagnosed with lung neoplasm malignant and was treated with Tarceva (View Usage). After Tarceva was administered, patient had the following side effects: dialysis (What is dialysis?), pleural effusion, renal failure acute, urinary retention. Tarceva dosage: (150 Mg,qd), Oral. Patient was hospitalized.

6780874-X | Aortic Aneurysm, Carcinoid Tumour Of The Pancreas, Malignant Neoplasm Progression, Pain, Rash
Patient was taking Tarceva (View Usage). Patient experienced the following unwanted or unexpected effects: aortic aneurysm (What is aortic aneurysm?), carcinoid tumour of the pancreas, malignant neoplasm progression, pain (What is pain?), rash (What is rash?) on May 31, 2010 from POLAND Additional patient health information: Male patient , 62 years of age, . Tarceva dosage: (100 Mg,qd), Oral. During the same period patient was treated with GEMCITABINE (View Gemcitabine Review and Gemcitabine Label ).

6780873-8 | Back Pain, Malignant Neoplasm Progression, Malignant Splenic Neoplasm
Adverse event was reported on May 31, 2010 by a Female patient taking Tarceva (View Usage) (Dosage: (150 Mg,qd), Oral) was diagnosed with malignant splenic neoplasm and. Location: BRAZIL , 50 years of age, Patient had the following side effects: back pain (What is back pain?), malignant neoplasm progression, malignant splenic neoplasm. Patient was hospitalized.

6772447-X | Haematuria
on May 28, 2010 Male patient from CHINA , 70 years of age, was diagnosed with non-small cell lung cancer and was treated with Tarceva (View Usage). After Tarceva was administered, patient had the following side effects: haematuria. Tarceva dosage: 150 Mg, Qd; Oral.

6772362-1 | Acquired Epidermolysis Bullosa
on May 28, 2010 Female patient from ITALY , 44 years of age, was treated with Tarceva (View Usage). Patient experienced the following unwanted or unexpected effects: acquired epidermolysis bullosa. Tarceva dosage: 150 Mg, Qd, Oral. Patient was hospitalized.

6771691-5 | Disease Progression, Disorientation
Patient was taking Tarceva (View Usage). Patient had the following side effects: disease progression, disorientation on May 27, 2010 from JAPAN Additional patient health information: Male patient , 82 years of age, weighting 106.3 lb, . Tarceva dosage: 100 Mg, Qd, Oral. During the same period patient was treated with ENALAPRIL MALEATE (View Enalapril Maleate Review and Enalapril Maleate Label ), SERMION (NICERGOLINE) (View Sermion (nicergoline) Review and Sermion (nicergoline) Label ), URINORM (BENZBROMARONE) (View Urinorm (benzbromarone) Review and Urinorm (benzbromarone) Label ), NAUZELIN (DOMPERIDONE) (View Nauzelin (domperidone) Review and Nauzelin (domperidone) Label ), LANSOPRAZOLE (View Lansoprazole Review and Lansoprazole Label ), ADALAT (View Adalat Review and Adalat Label ), MUCOSOLVAN (AMBROXOL HYDROCHLORIDE) (View Mucosolvan (ambroxol Hydrochloride) Review and Mucosolvan (ambroxol Hydrochloride) Label ), TIOTROPIUM BROMIDE (View Tiotropium Bromide Review and Tiotropium Bromide Label ).

6771552-1 | Disease Progression, Mouth Ulceration, Parkinsonism, Pleural Effusion, Skin Toxicity
Adverse event was reported on May 27, 2010 by a Female patient taking Tarceva (View Usage) (Dosage: Oral) was diagnosed with antiemetic supportive care and. Location: UNITED KINGDOM , 73 years of age, After Tarceva was administered, patient had the following side effects: disease progression, mouth ulceration, parkinsonism, pleural effusion, skin toxicity. During the same period patient was treated with METOCLOPRAMIDE (View Metoclopramide Review and Metoclopramide Label ), BENDROFLUAZIDE (BENDROFLUAZIDE) (View Bendrofluazide (bendrofluazide) Review and Bendrofluazide (bendrofluazide) Label ), RAMIPRIL (View Ramipril Review and Ramipril Label ), ADCAL (CARBAZOCHROME) (View Adcal (carbazochrome) Review and Adcal (carbazochrome) Label ), ALENDRONIC ACID (ALENDRONIC ACID) (View Alendronic Acid (alendronic Acid) Review and Alendronic Acid (alendronic Acid) Label ).

6768139-3 | Dyspnoea
on May 26, 2010 Female patient from MALAYSIA , 48 years of age, was diagnosed with lung neoplasm malignant and was treated with Tarceva (View Usage). Patient experienced the following unwanted or unexpected effects: dyspnoea. Tarceva dosage: 150 Mg, Qd, Oral. During the same period patient was treated with DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ), MORPHINE (View Morphine Review and Morphine Label ), BISACODYL (BISACODYL) (View Bisacodyl (bisacodyl) Review and Bisacodyl (bisacodyl) Label ), MIDAZOLAM HCL (View Midazolam Hcl Review and Midazolam Hcl Label ), OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ).

6768138-1 | Diarrhoea, Dry Skin, Oedema Peripheral, Paronychia
on May 26, 2010 Female patient from MALAYSIA , 60 years of age, was diagnosed with lung neoplasm malignant and was treated with Tarceva (View Usage). Patient had the following side effects: diarrhoea, dry skin, oedema peripheral, paronychia. Tarceva dosage: 150 Mg, Oral. During the same period patient was treated with PYRIDOXINE (PYRIDOXINE) (View Pyridoxine (pyridoxine) Review and Pyridoxine (pyridoxine) Label ), DIPHENOXYLATE (DIPHENOXYLATE) (View Diphenoxylate (diphenoxylate) Review and Diphenoxylate (diphenoxylate) Label ), MULTIVITAMIN NOS (View Multivitamin Nos Review and Multivitamin Nos Label ).

6766906-3 | Diarrhoea
Patient was taking Tarceva (View Usage). After Tarceva was administered, patient had the following side effects: diarrhoea on May 25, 2010 from JAPAN Additional patient health information: Female patient , 64 years of age, was diagnosed with non-small cell lung cancer and. Tarceva dosage: (150 Mg,qd),oral.

6763936-2 | Blood Glucose Increased, Cheilosis, Confusional State, Dehydration, Dry Mouth, Fatigue, Somnolence
Adverse event was reported on May 24, 2010 by a Male patient taking Tarceva (View Usage) (Dosage: 1800 Mg Oral) was diagnosed with adenocarcinoma pancreas and. Location: UNITED STATES , 76 years of age, Patient experienced the following unwanted or unexpected effects: blood glucose increased, cheilosis, confusional state, dehydration, dry mouth, fatigue, somnolence. During the same period patient was treated with GEMCITABINE HYDROCHLORIDE (5880 Mg Intravenous) (View Gemcitabine Hydrochloride Review and Gemcitabine Hydrochloride Label ). Patient was hospitalized.

6763935-0 | Abasia, Decubitus Ulcer, Multiple Sclerosis Relapse, Wheelchair User
on May 24, 2010 Male patient from UNITED STATES , 67 years of age, was diagnosed with pancreatic carcinoma stage iv and was treated with Tarceva (View Usage). Patient had the following side effects: abasia, decubitus ulcer, multiple sclerosis relapse, wheelchair user. Tarceva dosage: 100 Mg Qd Oral.

6763496-6 | Blood Pressure Decreased, Cardiac Arrest, Condition Aggravated, Decreased Appetite, Depressed Level Of Consciousness, Lethargy, Malaise, Metastases To Bone, Mobility Decreased
on May 24, 2010 Female patient from JAPAN , 75 years of age, was diagnosed with lung adenocarcinoma and was treated with Tarceva (View Usage). After Tarceva was administered, patient had the following side effects: blood pressure decreased, cardiac arrest (What is cardiac arrest?), condition aggravated, decreased appetite, depressed level of consciousness, lethargy, malaise, metastases to bone, mobility decreased. Tarceva dosage: (50 Mg, Qd), Oral. During the same period patient was treated with OXYCONTIN (View Oxycontin Review and Oxycontin Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ), LORCAM (View Lorcam Review and Lorcam Label ), MUCOSTA (REBAMIPIDE) (View Mucosta (rebamipide) Review and Mucosta (rebamipide) Label ), LOSARTAN POTASSIUM (View Losartan Potassium Review and Losartan Potassium Label ). Patient was hospitalized.

6763281-5 | Acute Myocardial Infarction, Acute Respiratory Failure, Hypophagia, Hypotension, Hypoxia, Malaise, Myocardial Ischaemia, No Therapeutic Response, Nosocomial Infection
Patient was taking Tarceva (View Usage). Patient experienced the following unwanted or unexpected effects: acute myocardial infarction, acute respiratory failure, hypophagia, hypotension, hypoxia, malaise, myocardial ischaemia, no therapeutic response, nosocomial infection on Jun 08, 2010 from UNITED STATES Additional patient health information: Male patient , weighting 145.1 lb, . Tarceva dosage: 14550 Mg. Patient was hospitalized.

6759485-8 | Blood Lactate Dehydrogenase Increased, Haemoptysis, Hirsutism, Paronychia, Skin Hyperpigmentation
Adverse event was reported on May 19, 2010 by a Female patient taking Tarceva (View Usage) (Dosage: (150 Mg,qd), Oral) was diagnosed with non-small cell lung cancer and. Location: ROMANIA , 51 years of age, Patient had the following side effects: blood lactate dehydrogenase increased, haemoptysis, hirsutism, paronychia, skin hyperpigmentation. During the same period patient was treated with CODEINE SUL TAB (View Codeine Sul Tab Review and Codeine Sul Tab Label ), ALPRAZOLAM (View Alprazolam Review and Alprazolam Label ). Patient was hospitalized.

6759013-7 | Anaemia, Haematoma, Thrombocytopenia
on May 19, 2010 Female patient from PORTUGAL , 74 years of age, weighting 149.9 lb, was diagnosed with non-small cell lung cancer and was treated with Tarceva (View Usage). After Tarceva was administered, patient had the following side effects: anaemia, haematoma, thrombocytopenia. Tarceva dosage: (150 Mg), Oral. During the same period patient was treated with NOLOTIL (View Nolotil Review and Nolotil Label ), DEFLAZACORT (DEFLAZACORT) (View Deflazacort (deflazacort) Review and Deflazacort (deflazacort) Label ), DICLOFENAC SODIUM (View Diclofenac Sodium Review and Diclofenac Sodium Label ), FENTANYL 100 (View Fentanyl-100 Review and Fentanyl-100 Label ). Patient was hospitalized.

6756160-0 | Dyspnoea, Hypoxia
on Jun 03, 2010 Male patient from UNITED STATES , 73 years of age, weighting 127.0 lb, was treated with Tarceva (View Usage). Patient experienced the following unwanted or unexpected effects: dyspnoea, hypoxia. Tarceva dosage: . During the same period patient was treated with AVASTIN (View Avastin Review and Avastin Label ). Patient was hospitalized.

6754411-X | Cholelithiasis
Patient was taking Tarceva (View Usage). Patient had the following side effects: cholelithiasis on May 14, 2010 from JAPAN Additional patient health information: Female patient , 74 years of age, was diagnosed with lung adenocarcinoma and. Tarceva dosage: (100 Mg, Qd), Oral; Oral. During the same period patient was treated with OXYCONTIN (View Oxycontin Review and Oxycontin Label ), FAMOTIDINE (View Famotidine Review and Famotidine Label ), LOXOPROFEN (LOXOPROFEN) (View Loxoprofen (loxoprofen) Review and Loxoprofen (loxoprofen) Label ), ZOLPIDEM TARTRATE (View Zolpidem Tartrate Review and Zolpidem Tartrate Label ), MAGNESIUM OXIDE (MAGNESIUM OXIDE) (View Magnesium Oxide (magnesium Oxide) Review and Magnesium Oxide (magnesium Oxide) Label ), VALSARTAN (View Valsartan Review and Valsartan Label ), DOXAZOSIN MESYLATE (View Doxazosin Mesylate Review and Doxazosin Mesylate Label ). Patient was hospitalized.

6754391-7 | Acquired Epidermolysis Bullosa
Adverse event was reported on May 15, 2010 by a Female patient taking Tarceva (View Usage) (Dosage: (150 Mg, Qd), Oral) . Location: ITALY , 44 years of age, After Tarceva was administered, patient had the following side effects: acquired epidermolysis bullosa. Patient was hospitalized.

6754085-8 | Haemorrhage
on May 17, 2010 Male patient from UNITED STATES , 54 years of age, was diagnosed with pancreatic carcinoma and was treated with Tarceva (View Usage). Patient experienced the following unwanted or unexpected effects: haemorrhage. Tarceva dosage: (100 Mg,qd),oral.

6754071-8 | Haemoptysis, Vocal Cord Paralysis
on May 17, 2010 Female patient from UNITED STATES , weighting 108.0 lb, was diagnosed with non-small cell lung cancer and was treated with Tarceva (View Usage). Patient had the following side effects: haemoptysis, vocal cord paralysis. Tarceva dosage: (150 Mg,qd),oral. During the same period patient was treated with OXYCONTIN (View Oxycontin Review and Oxycontin Label ).

6754049-4 | Acute Respiratory Failure, Lung Neoplasm Malignant, Malignant Neoplasm Progression, Pneumonia, Pulmonary Embolism
Patient was taking Tarceva (View Usage). After Tarceva was administered, patient had the following side effects: acute respiratory failure, lung neoplasm malignant, malignant neoplasm progression, pneumonia (What is pneumonia?), pulmonary embolism (What is pulmonary embolism?) on May 14, 2010 from UNITED STATES Additional patient health information: Female patient , 50 years of age, was diagnosed with lung neoplasm malignant and. Tarceva dosage: 100 Mg,qd, Oral. Patient was hospitalized.

6753061-9 | Haemorrhage
Adverse event was reported on Jun 02, 2010 by a Male patient taking Tarceva (View Usage) (Dosage: 1 Pill Daily Mouth) was diagnosed with neoplasm malignant and. Location: UNITED STATES , 53 years of age, weighting 155.0 lb, Patient experienced the following unwanted or unexpected effects: haemorrhage.

6752775-4 | Asthenia, Chest Pain, Haemoglobin Decreased, Hypotension, Leukopenia, Neutropenia, Productive Cough
on Jun 02, 2010 Male patient from UNITED STATES , weighting 145.9 lb, was diagnosed with neoplasm and was treated with Tarceva (View Usage). Patient had the following side effects: asthenia, chest pain (What is chest pain?), haemoglobin decreased, hypotension, leukopenia, neutropenia, productive cough. Tarceva dosage: 150 Day 1 Through 28 Po. During the same period patient was treated with VIDAZA (190 Mg Day 104, Day 15-18) (View Vidaza Review and Vidaza Label ), FENTANYL 75 (View Fentanyl-75 Review and Fentanyl-75 Label ), PERCOCET (View Percocet Review and Percocet Label ), DIGOXIN (View Digoxin Review and Digoxin Label ), CARVEDILOL (View Carvedilol Review and Carvedilol Label ), LISINORIL (View Lisinoril Review and Lisinoril Label ). Patient was hospitalized.

6751735-7 | Infection, Pneumonia
on May 13, 2010 Female patient from JAPAN , 75 years of age, was diagnosed with lung adenocarcinoma and was treated with Tarceva (View Usage). After Tarceva was administered, patient had the following side effects: infection (What is infection?), pneumonia (What is pneumonia?). Tarceva dosage: 100 Mg, Qd, Oral.

6751356-6 | Anger, Contusion, Depressed Level Of Consciousness, Eye Discharge, Faecal Incontinence, Fall, Frustration, Gait Disturbance, Irritability
Patient was taking Tarceva (View Usage). Patient experienced the following unwanted or unexpected effects: anger, contusion, depressed level of consciousness, eye discharge, faecal incontinence, fall (What is fall?), frustration, gait disturbance, irritability on May 12, 2010 from JAPAN Additional patient health information: Female patient , 75 years of age, weighting 105.3 lb, was diagnosed with lung adenocarcinoma and. Tarceva dosage: (100 Mg,qd),oral. During the same period patient was treated with URSO 250 (View Urso 250 Review and Urso 250 Label ), MAGNESIUM OXIDE (MAGNESIUM OXIDE) (View Magnesium Oxide (magnesium Oxide) Review and Magnesium Oxide (magnesium Oxide) Label ), HIBON (RIBOFLAVIN TETRABUTYRATE) (View Hibon (riboflavin Tetrabutyrate) Review and Hibon (riboflavin Tetrabutyrate) Label ), PYDOXAL (PYRIDOXAL PHOSPHATE) (View Pydoxal (pyridoxal Phosphate) Review and Pydoxal (pyridoxal Phosphate) Label ), PERINDOPRIL ERBUMINE (View Perindopril Erbumine Review and Perindopril Erbumine Label ), LIVALO (View Livalo Review and Livalo Label ), VALSARTAN (View Valsartan Review and Valsartan Label ). Patient was hospitalized.

6751024-0 | Alveolitis, Dyspnoea, Pulmonary Embolism
Adverse event was reported on May 12, 2010 by a Male patient taking Tarceva (View Usage) (Dosage: (100 Mg,qd), Oral) was diagnosed with pancreatic carcinoma and. Location: GERMANY , 60 years of age, Patient had the following side effects: alveolitis, dyspnoea, pulmonary embolism (What is pulmonary embolism?). During the same period patient was treated with GRANISETRON HCL (View Granisetron Hcl Review and Granisetron Hcl Label ), LANTUS (View Lantus Review and Lantus Label ), KREON (PANCREATIN) (View Kreon (pancreatin) Review and Kreon (pancreatin) Label ), FENTANYL 100 (View Fentanyl-100 Review and Fentanyl-100 Label ), GLYBURIDE (GLIBENCBAMIDE) (View Glyburide (glibencbamide) Review and Glyburide (glibencbamide) Label ), GEMCITABINE (View Gemcitabine Review and Gemcitabine Label ). Patient was hospitalized.

6751002-1 | Disseminated Intravascular Coagulation, Interstitial Lung Disease, Platelet Count Decreased, Pneumonia Aspiration, Urticaria
on May 11, 2010 Male patient from JAPAN , 67 years of age, was diagnosed with non-small cell lung cancer and was treated with Tarceva (View Usage). After Tarceva was administered, patient had the following side effects: disseminated intravascular coagulation, interstitial lung disease, platelet count decreased, pneumonia aspiration, urticaria. Tarceva dosage: (100 Mg, Qd), Oral. During the same period patient was treated with TIAPRIDE HYDROCHLORIDE (TIAPRIDE HYDROCHLORIDE) (View Tiapride Hydrochloride (tiapride Hydrochloride) Review and Tiapride Hydrochloride (tiapride Hydrochloride) Label ), TICLOPIDINE HCL (View Ticlopidine Hcl Review and Ticlopidine Hcl Label ), LANSOPRAZOLE (View Lansoprazole Review and Lansoprazole Label ).

6750627-7 | Cough, Dyspnoea, Effusion, Haemorrhage, Rash Pruritic
on May 12, 2010 Male patient from CYPRUS , 76 years of age, was diagnosed with non-small cell lung cancer and was treated with Tarceva (View Usage). Patient experienced the following unwanted or unexpected effects: cough, dyspnoea, effusion, haemorrhage, rash pruritic. Tarceva dosage: (150 Mg, Qd), Oral. During the same period patient was treated with DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ), FOLIC ACID (View Folic Acid Review and Folic Acid Label ), VITAMIN E (View Vitamin E Review and Vitamin E Label ). Patient was hospitalized.

6750591-0 | Dehydration, Feeling Abnormal, Malignant Neoplasm Progression, Salivary Gland Cancer, Urinary Tract Infection, Weight Decreased
Patient was taking Tarceva (View Usage). Patient had the following side effects: dehydration, feeling abnormal, malignant neoplasm progression, salivary gland cancer, urinary tract infection (What is urinary tract infection?), weight decreased on May 28, 2010 from UNITED STATES Additional patient health information: Male patient , weighting 160.5 lb, was diagnosed with salivary gland cancer and. Tarceva dosage: 150 Mg Day 1-28 Po. During the same period patient was treated with VIDAZA (190 Mg Day 1-4, Day 15-18 Sq) (View Vidaza Review and Vidaza Label ). Patient was hospitalized.

6749751-4 | Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Asthenia, Blood Bilirubin Increased, Cardiac Operation, Chest Pain, Dermatitis, Diarrhoea, Feeling Abnormal
Adverse event was reported on May 12, 2010 by a Female patient taking Tarceva (View Usage) (Dosage: 150 Mg, Qd, Oral) was diagnosed with non-small cell lung cancer, phlebitis, skin disorder and. Location: POLAND , 74 years of age, After Tarceva was administered, patient had the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, asthenia, blood bilirubin increased, cardiac operation, chest pain (What is chest pain?), dermatitis, diarrhoea, feeling abnormal. During the same period patient was treated with BUTAPIRAZOL (PHENYLBUTAZONE) (2x Per Day, Topical) (View Butapirazol (phenylbutazone) Review and Butapirazol (phenylbutazone) Label ), HEPARIN (Topical) (View Heparin Review and Heparin Label ), LORINDEN (FLUMETASONE PIVALATE) (2x Per Day, Topical) (View Lorinden (flumetasone Pivalate) Review and Lorinden (flumetasone Pivalate) Label ), CLODRONIC ACID (CLODRONIC ACID) (View Clodronic Acid (clodronic Acid) Review and Clodronic Acid (clodronic Acid) Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), HEPATIL (ORNITHINE ASPARTATE) (View Hepatil (ornithine Aspartate) Review and Hepatil (ornithine Aspartate) Label ), BISOPROLOL FUMARATE (View Bisoprolol Fumarate Review and Bisoprolol Fumarate Label ), HEPAREGEN (TIMONACIC) (View Heparegen (timonacic) Review and Heparegen (timonacic) Label ). Patient was hospitalized.

6746361-X | Malignant Neoplasm Progression
on May 11, 2010 Female patient from COLOMBIA , 59 years of age, was diagnosed with lung neoplasm malignant and was treated with Tarceva (View Usage). Patient experienced the following unwanted or unexpected effects: malignant neoplasm progression. Tarceva dosage: 150 Mg, Qd, Oral. During the same period patient was treated with ACETAMINOPHEN (View Acetaminophen Review and Acetaminophen Label ).

6746360-8 | Cardiopulmonary Failure, Dyspnoea
on May 11, 2010 Male patient from COLOMBIA , 70 years of age, was diagnosed with lung neoplasm malignant and was treated with Tarceva (View Usage). Patient had the following side effects: cardiopulmonary failure, dyspnoea. Tarceva dosage: 150 Mg, Qd, Oral. Patient was hospitalized.

6743109-X | Lichen Planus
Patient was taking Tarceva (View Usage). After Tarceva was administered, patient had the following side effects: lichen planus on May 10, 2010 from AUSTRALIA Additional patient health information: Male patient , 79 years of age, was diagnosed with lung adenocarcinoma and. Tarceva dosage: (100 Mg), Oral.

6743108-8 | Interstitial Lung Disease, Leukopenia
Adverse event was reported on May 10, 2010 by a Female patient taking Tarceva (View Usage) (Dosage: (150 Mg, Qd), Oral) was diagnosed with non-small cell lung cancer and. Location: JAPAN , 66 years of age, weighting 88.85 lb, Patient experienced the following unwanted or unexpected effects: interstitial lung disease, leukopenia. During the same period patient was treated with GABAPENTIN ((200 Mg, Qd), Oral) (View Gabapentin Review and Gabapentin Label ), MUCOSTA (REBAMIPIDE) (View Mucosta (rebamipide) Review and Mucosta (rebamipide) Label ), RABEPRAZOLE SODIUM (View Rabeprazole Sodium Review and Rabeprazole Sodium Label ), PRAVASTATIN (View Pravastatin Review and Pravastatin Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ), GASMOTIN (MOSAPRIDE CITRATE) (View Gasmotin (mosapride Citrate) Review and Gasmotin (mosapride Citrate) Label ), LENDORM (View Lendorm Review and Lendorm Label ), MYONAL (EPERISONE HYDROCHLORIDE) (View Myonal (eperisone Hydrochloride) Review and Myonal (eperisone Hydrochloride) Label ).

6741384-9 | Corneal Disorder, Dermatitis Acneiform, Diarrhoea, Dry Mouth, Electrolyte Imbalance, Hair Growth Abnormal, Mucous Membrane Disorder, Muscle Spasms, Onychomadesis
on May 09, 2010 Female patient from POLAND , 72 years of age, was diagnosed with lung neoplasm malignant and was treated with Tarceva (View Usage). Patient had the following side effects: corneal disorder, dermatitis acneiform, diarrhoea, dry mouth, electrolyte imbalance, hair growth abnormal, mucous membrane disorder, muscle spasms, onychomadesis. Tarceva dosage: (150 Mg,qd),oral.

6738878-9 | Alopecia, Alopecia Scarring, Rash, Skin Disorder
on May 05, 2010 Female patient from IRELAND , 51 years of age, weighting 134.5 lb, was diagnosed with non-small cell lung cancer and was treated with Tarceva (View Usage). After Tarceva was administered, patient had the following side effects: alopecia, alopecia scarring, rash (What is rash?), skin disorder. Tarceva dosage: 75 Mg, Oral. During the same period patient was treated with OXYCONTIN (View Oxycontin Review and Oxycontin Label ).

6737342-0 | Product Name Confusion
Patient was taking Tarceva (View Usage). Patient experienced the following unwanted or unexpected effects: product name confusion on May 21, 2010 from UNITED STATES Additional patient health information: Female patient , 72 years of age, was diagnosed with neoplasm malignant, blood pressure (What is blood pressure?) and. Tarceva dosage: 30 Qd Po. During the same period patient was treated with TEKTURNA (View Tekturna Review and Tekturna Label ).

6734626-7 | Blood Urine Present, Nephrolithiasis, Renal Impairment
Adverse event was reported on May 04, 2010 by a Female patient taking Tarceva (View Usage) (Dosage: 125 Mg,qd,oral) was diagnosed with lung neoplasm malignant and. Location: UNITED STATES , 77 years of age, Patient had the following side effects: blood urine present, nephrolithiasis, renal impairment.

6733044-5 | Cardiopulmonary Failure, Disease Progression, Lung Neoplasm Malignant
on Apr 30, 2010 Female patient from COLOMBIA , 74 years of age, was diagnosed with lung neoplasm malignant and was treated with Tarceva (View Usage). After Tarceva was administered, patient had the following side effects: cardiopulmonary failure, disease progression, lung neoplasm malignant. Tarceva dosage: 150 Mg, Qd, Oral.

6733043-3 | Cardiopulmonary Failure
on Apr 30, 2010 Male patient from COLOMBIA , 79 years of age, was diagnosed with lung neoplasm malignant and was treated with Tarceva (View Usage). Patient experienced the following unwanted or unexpected effects: cardiopulmonary failure. Tarceva dosage: 150 Mg, Qd, Oral. Patient was hospitalized.

6733042-1 | Cardiopulmonary Failure, Dyspnoea
Patient was taking Tarceva (View Usage). Patient had the following side effects: cardiopulmonary failure, dyspnoea on Apr 30, 2010 from COLOMBIA Additional patient health information: Male patient , 64 years of age, was diagnosed with lung neoplasm malignant and. Tarceva dosage: 150 Mg, Qd, Oral. Patient was hospitalized.